Mop
Simple answer - yes, most definitely.
An interesting challenge for the Australian and other govts with the backlash over last year's oversupply of H1N1 vaccine.
Each year, there is a new vaccine to cover the latest strains of influenza. Therefore, it is a very costly exercise for govts (and a lucrative one for vaccine suppliers) to stock/supply annually.
Traditionally, the vaccines have been targeted to the very young, the elderly and those with disabilities and/or lower immune systems, although over the years, many GPs have been recommending annual vaccinations to a broader spectrum of the population...but of all the people who have the vaccine, only x% would catch the flu if they do not have a vaccination.
Swine Flu obviously caused a more blanket approach again and hence, the problems facing govts now...
It is likely that the approach has reverted to the traditional one and govts have cut their spending on vaccines and indeed are focusing more on the more cost-effective anti-viral approach.
This is obviously great news for Biota and with LANI not far off, this underpins the traditional approach to vaccinations, with a single dose and far more effective anticiral as the second line of defence for the majority of the population.
- Forums
- ASX - By Stock
- BTA
- ds to start production of lani
ds to start production of lani, page-11
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add BTA (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online